Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial

Haematologica

Volumn 89, Issue 3, 2004, Pages 371-373

  Glasmacher, Axel ^a,h   Goldschmidt, Hartmut ^b   Mezger, Jörg ^a,c   Haferlach, Torsten ^d,e   Schmidt Wolf, Ingo G H ^a   Gieseler, Frank ^f,g  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c St Vincentius Krankenh   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Idarubicin; Multiple myeloma; Oral application; Refractory disease; VID

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; DEATH; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SEPSIS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; IDARUBICIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; VINCRISTINE;

EID: 2942740800     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens MR, et al. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997;11 Suppl 5:S22-6.
2. Cook G, Sharp RA, Tansey P, Franklin IM. A phase 1/11 trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 1996;93:931-4.
3. Barlogie B, Alexanian R. Therapy of primary resistant and relapsed multiple myeloma. Onkologie 1986;9:210-4.
4. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30.
5. Palva IP, Ahrenberg P, Ala Harja K, Almqvist A, Elonen E, Hallman H, et al. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish leukaemia group. Eur J Haematol 1990;44:121-4.
6. Dalton WS, Crowley J, Salmon S, Grogan TM, Laufman LR, Weiss GR, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. Cancer 1995;75:815-20.
7. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326-30.
8. Mineur P, Menard JF, Le Loet X, Bernard JF, Grosbois B, Pollet JP, et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 1998;103:512-7.
9. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
10. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.